CeQur raises usd 115 Million Series C5 Financing Round

CeQur, a Swiss medical device company, announced the close of an oversubscribed $115 million equity financing.

The company will use the funds to advance commercial plans for CeQur Simplicity, including market development activities, a phased commercial launch strategy that includes a limited market release in 2021, and the scale-up of high-volume manufacturing. CeQur Simplicity is both FDA cleared and CE-marked.

Credit Suisse Entrepreneur Capital Ltd and Endeavour Vision led the financing with significant participation from new investors, including Tandem Diabetes Care, Inc. (NASDAQ: TNDM), Ypsomed Group (SWX: YPSN), Federated Hermes Kaufmann Funds, Kingdon Capital, and GMS Capital, as well as existing investors, Schroder & Co. Bank SA, and VI Partners.

Walder Wyss advised CeQur SA in the financing with a team  led by Patrick W. Vogel (Partner, Corporate/M&A) and included André Kuhn (Managing Associate, Corporate/M&A), Camille Tistounet (Trainee Lawyer) and Leandro Schafer (Trainee Lawyer).